{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:01:22Z","timestamp":1791468082900,"version":"4.3.4"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300247"],"award-info":[{"award-number":["82300247"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.intimp.2026.117465","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:38:44Z","timestamp":1790599124000},"page":"117465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical management strategies for cytokine release syndrome and their impact on CAR T-cell efficacy in lymphoma"],"prefix":"10.1016","volume":"190","author":[{"given":"Kaihang","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117465_bb0005","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117465_bb0010","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2026.117465_bb0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.117465_bb0020","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.117465_bb0025","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.intimp.2026.117465_bb0030","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117465_bb0035","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2026.117465_bb0040","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1039\/D2TB00592A","article-title":"Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy","volume":"10","author":"Balagopal","year":"2022","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.intimp.2026.117465_bb0045","article-title":"Strategies for reducing toxicity and enhancing efficacy of chimeric antigen receptor T cell therapy in hematological malignancies","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117465_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.693016","article-title":"CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities","volume":"12","author":"Fischer","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117465_bb0055","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1158\/1078-0432.CCR-24-0830","article-title":"Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B-cell lymphoma","volume":"30","author":"Hubbeling","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117465_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061747","article-title":"Long-term follow-up of bridging therapies prior to CAR T-cell therapy for relapsed\/refractory large B cell lymphoma","volume":"15","author":"Ladbury","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117465_bb0065","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1182\/bloodadvances.2023011489","article-title":"Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US lymphoma CAR-T consortium","volume":"8","author":"Jain","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.117465_bb0070","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.117465_bb0075","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jcyt.2022.03.009","article-title":"Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma","volume":"24","author":"Sun","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.intimp.2026.117465_bb0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.radonc.2022.10.018","article-title":"Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed\/refractory aggressive B-cell lymphoma","volume":"177","author":"Yu","year":"2022","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.intimp.2026.117465_bb0085","first-page":"876","article-title":"Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis","volume":"111","author":"Alhomoud","year":"2026","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2026.117465_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1481080","article-title":"Hyper-fractionated radiotherapy as a bridging strategy to enhance CAR-T efficacy by regulating T-cell co-stimulatory molecules in relapsed\/refractory diffuse large B-cell lymphoma","volume":"15","author":"Ruan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117465_bb0095","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.17738","article-title":"The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma","volume":"195","author":"Lutfi","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2026.117465_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32030173","article-title":"Enhancing CAR-T efficacy in large B-cell lymphoma with radiation bridging therapy: a real-world single-center experience","volume":"32","author":"Laverdure","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.intimp.2026.117465_bb0105","article-title":"Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry","volume":"9","author":"Galtier","year":"2025","journal-title":"Hemasphere"},{"key":"10.1016\/j.intimp.2026.117465_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109580","article-title":"Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy","volume":"183","author":"Fan","year":"2023","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.intimp.2026.117465_bb0115","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.117465_bb0120","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00432-024-05765-8","article-title":"Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed\/refractory large B-cell lymphoma: findings from a German monocentric study","volume":"150","author":"Eigendorff","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117465_bb0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-024-01022-w","article-title":"Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma","volume":"14","author":"Keijzer","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.intimp.2026.117465_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1517348","article-title":"Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas","volume":"16","author":"Manzar","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117465_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1633644","article-title":"Real-world Australian experience with tisagenlecleucel for relapsed\/refractory diffuse large B-cell lymphoma-importance of pre-CAR-T optimization","volume":"15","author":"Ho","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.117465_bb0140","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/bloodadvances.2022008240","article-title":"Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL","volume":"7","author":"Zurko","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.117465_bb0145","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41409-025-02539-9","article-title":"Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma","volume":"60","author":"Canelo-Vilaseca","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.intimp.2026.117465_bb0150","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2026.117465_bb0155","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2026.117465_bb0160","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117465_bb0165","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117465_bb0170","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1182\/bloodadvances.2023010302","article-title":"Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma","volume":"7","author":"Scordo","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.117465_bb0175","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117465_bb0180","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117465_bb0185","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008975","article-title":"Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma","volume":"12","author":"Bharadwaj","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117465_bb0190","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1182\/bloodadvances.2023011492","article-title":"Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines","volume":"8","author":"Ghilardi","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.117465_bb0195","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.annonc.2022.05.521","article-title":"Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas","volume":"33","author":"Ghilardi","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2026.117465_bb0200","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/ajh.27069","article-title":"Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma","volume":"98","author":"Ong","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.intimp.2026.117465_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.03.012","article-title":"Comparative efficacy of bendamustine versus fludarabine\/cyclophosphamide for lymphodepletion before chimeric antigen receptor T-cell therapy in lymphoma","volume":"31","author":"Rao","year":"2025","journal-title":"Transplant. Cell Ther."},{"key":"10.1016\/j.intimp.2026.117465_bb0210","doi-asserted-by":"crossref","first-page":"429.e421","DOI":"10.1016\/j.jtct.2023.03.019","article-title":"Impact of preemptive use of tocilizumab on chimeric antigen receptor T cell outcomes in non-Hodgkin lymphoma","volume":"29","author":"De Philippis","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"10.1016\/j.intimp.2026.117465_bb0215","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2026.117465_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117465_bb0225","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1007\/s00277-025-06511-x","article-title":"Prophylactic tocilizumab prior to infusion of CD19 CAR T-cells reduces therapy-related complications in older lymphoma patients","volume":"104","author":"Stolz","year":"2025","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.intimp.2026.117465_bb0230","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jtct.2024.08.018","article-title":"Tocilizumab prophylaxis following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Transplant Cell. Ther."},{"key":"10.1016\/j.intimp.2026.117465_bb0235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117465_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009504","article-title":"Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacy","volume":"18","author":"Brummer","year":"2022","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.intimp.2026.117465_bb0245","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12967-024-05063-4","article-title":"CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude","volume":"22","author":"Poiret","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117465_bb0250","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117465_bb0255","doi-asserted-by":"crossref","first-page":"573.e571","DOI":"10.1016\/j.jtct.2023.06.018","article-title":"Negative prognostic impact of high-dose or long-term corticosteroid use in patients with relapsed or refractory B-cell lymphoma who received tisagenlecleucel","volume":"29","author":"Terao","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"10.1016\/j.intimp.2026.117465_bb0260","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene Ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117465_bb0265","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"195","author":"Topp","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2026.117465_bb0270","doi-asserted-by":"crossref","DOI":"10.3390\/biom13020382","article-title":"Early use of corticosteroids following CAR T-cell therapy correlates with reduced risk of high-grade CRS without negative impact on neurotoxicity or treatment outcome","volume":"13","author":"Lakomy","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2026.117465_bb0275","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2026.117465_bb0280","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41409-023-02169-z","article-title":"Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids","volume":"59","author":"Oluwole","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.intimp.2026.117465_bb0285","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2026.117465_bb0290","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.bbmt.2020.06.008","article-title":"Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed\/refractory large B cell lymphoma","volume":"26","author":"Oluwole","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.intimp.2026.117465_bb0295","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.117465_bb0300","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2024-207807","article-title":"Influence of siltuximab for CAR T-cell related CRS\/Icans on CAR T-cell reconstitution, function, and clinical outcomes","volume":"144","author":"Di Stasi","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117465_bb0305","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2018.09.024","article-title":"American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States","volume":"25","author":"Mahmoudjafari","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.intimp.2026.117465_bb0310","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/bloodadvances.2024013688","article-title":"Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis","volume":"9","author":"Bajwa","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.117465_bb0315","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41421-021-00299-6","article-title":"Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy","volume":"7","author":"Xue","year":"2021","journal-title":"Cell Discov."},{"key":"10.1016\/j.intimp.2026.117465_bb0320","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221988","article-title":"Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy","volume":"221","author":"Lin","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2026.117465_bb0325","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117465_bb0330","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117465_bb0335","article-title":"Therapeutic potential of TNF\u03b1 and IL1\u03b2 blockade for CRS\/ICANS in CAR-T therapy via ameliorating endothelial activation","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117465_bb0340","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117465_bb0345","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"10.1016\/j.intimp.2026.117465_bb0350","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117465_bb0355","series-title":"Abstracts of the Annual Meeting of the Japanese Society of Toxicology","article-title":"Therapeutic effect of anti-TNF-\u03b1 monoclonal antibody on cytokine release induced by CAR-T cells targeting CD22 [abstract]","author":"Cao","year":"2023"},{"key":"10.1016\/j.intimp.2026.117465_bb0360","article-title":"Benefits of chimeric antigen receptor T-cell therapy for B-cell lymphoma","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.intimp.2026.117465_bb0365","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117465_bb0370","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117465_bb0375","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005956","article-title":"Dasatinib for treatment of CAR T-cell therapy-related complications","volume":"10","author":"Baur","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117465_bb0380","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/ejh.70038","article-title":"Use of Dasatinib for the treatment of refractory immune effector cell-associated neurotoxicity syndrome after axicabtagene ciloleucel infusion: a case report","volume":"115","author":"Llata-Ortega","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.intimp.2026.117465_bb0385","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117465_bb0390","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41375-022-01572-7","article-title":"GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity","volume":"36","author":"Cox","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.117465_bb0395","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41421-021-00255-4","article-title":"CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy","volume":"7","author":"Yi","year":"2021","journal-title":"Cell Discov."},{"key":"10.1016\/j.intimp.2026.117465_bb0400","series-title":"Humanigen reports positive data with lenzilumab in the ZUMA-19 CAR-T phase 1b study in DLBCL and plans to initiate a potential registrational study. Business Wire","year":"2021"},{"key":"10.1016\/j.intimp.2026.117465_bb0405","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","article-title":"The addition of the BTK inhibitor Ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117465_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2026.105065","article-title":"Ibrutinib enhances stem-cell-memory T cell generation during early T cell activation but inhibits T cell proliferation","volume":"419","author":"He","year":"2026","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.intimp.2026.117465_bb0415","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CJI.0000000000000307","article-title":"Antitumor potency of an anti-CD19 chimeric antigen receptor T-cell therapy, lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib","volume":"43","author":"Qin","year":"2020","journal-title":"J. Immunother."},{"key":"10.1016\/j.intimp.2026.117465_bb0420","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2016.262","article-title":"Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms","volume":"31","author":"Ruella","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.117465_bb0425","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1111\/cas.14915","article-title":"Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma","volume":"112","author":"Liu","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.intimp.2026.117465_bb0430","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117465_bb0435","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood.V128.22.652.652","article-title":"Ruxolitinib prevents cytokine release syndrome after CART cell therapy without impairing the anti-tumor effect in a xenograft model","volume":"128","author":"Kenderian","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117465_bb0440","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbrc.2022.01.070","article-title":"Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells","volume":"595","author":"Xu","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2026.117465_bb0445","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy","volume":"26","author":"Huarte","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117465_bb0450","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood.2024026586","article-title":"Itacitinib for the prevention of IEC therapy\u2013associated CRS: results from the 2-part phase 2 INCB 39110-211 study","volume":"146","author":"Frigault","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117465_bb0455","doi-asserted-by":"crossref","first-page":"12686","DOI":"10.1182\/blood-2022-167715","article-title":"The dual PI3Kdg inhibitor Duvelisib potently inhibits cytokine release syndrome (CRS) while maintaining CAR-T function","volume":"140","author":"Amatya","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117465_bb0460","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1182\/blood-2023-172439","article-title":"Duvelisib for cytokine release syndrome prophylaxis during CD19-targeted CAR T cell therapy","volume":"142","author":"Slade","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117465_bb0465","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-020-01301-7","article-title":"Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome","volume":"20","author":"Wei","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.117465_bb0470","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1073\/pnas.1516485113","article-title":"T cell-intrinsic S1PR1 regulates endogenous effector T-cell egress dynamics from lymph nodes during infection","volume":"113","author":"Benechet","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2026.117465_bb0475","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15122695","article-title":"Polymeric particle BAM15 targeting macrophages attenuates the severity of LPS-induced sepsis: a proof of concept for specific immune cell-targeted therapy","volume":"15","author":"Udompornpitak","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.intimp.2026.117465_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114577","article-title":"Mitochondrial uncoupler BAM15 enhances the function of CD7CAR-T(CD7-) cells and reduces the release of cytokines for the therapy of T-cell malignancies","volume":"155","author":"Ma","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.117465_bb0485","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117465_bb0490","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","article-title":"Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma","volume":"25","author":"Wang","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.intimp.2026.117465_bb0495","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.117465_bb0500","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17060918","article-title":"Addition of phosphorous and IL6 to m-EASIX score improves detection of ICANS and CRS, as well as CRS progression","volume":"17","author":"Barker","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117465_bb0505","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-025-01338-1","article-title":"Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma","volume":"15","author":"Winkelmann","year":"2025","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.intimp.2026.117465_bb0510","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00259-022-06075-2","article-title":"Prognostic value of the international metabolic prognostic index for lymphoma patients receiving chimeric antigen receptor T-cell therapy","volume":"50","author":"Winkelmann","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926013123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926013123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:23:58Z","timestamp":1791465838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926013123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":102,"alternative-id":["S1567576926013123"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117465","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical management strategies for cytokine release syndrome and their impact on CAR T-cell efficacy in lymphoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117465"}}